Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

American Journal of Gastroenterology

Volumn 103, Issue 1, 2008, Pages 170-177

  Johanson, John F ^a,e   Morton, Dan ^b   Geenen, Joseph ^c   Ueno, Ryuji ^d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b GANT Research   (United States)

^c Gastroenterology Consultants Ltd   (United States)

^d Sucampo Pharmaceuticals Inc   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; CHLORIDE CHANNEL; FLEET ENEMA; LUBIPROSTONE; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STATISTICAL ANALYSIS;

ALPROSTADIL; CHLORIDE CHANNELS; CHRONIC DISEASE; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERISTALSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37849024665     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01524.x     Document Type: Article

References (28)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 2004 99 : 750 9.
2. Talley NJ. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991 101 : 927 34.
3. Talley NJ. Differentiating functional constipation from constipation-predominant irritable bowel syndrome: Management implications. Rev Gastroenterol Disord 2005 5 : 1 9.
4. Johanson JF, Kralstein J. Chronic constipation: A survey of the patient perspective. Aliment Pharmacol Ther 2007 25 : 599 608.
5. Bleser S, Brunton S, Carmichael B, et al. Management of chronic constipation: Recommendations from a consensus panel. J Fam Pract 2005 54 : 691 8.
6. Wald A. Diagnosis of constipation in primary and secondary care. Rev Gastroenterol Disord 2004 4 (Suppl 2 S28 33.
7. Locke GR, Pemberton JH, Phillips SF. AGA technical review on constipation. Gastroenterology 2000 119 : 1766 78.
8. Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005 100 : 232 42.
9. Fritz E, Hammer HF, Lipp RW, et al. Effects of lactulose and polyethylene glycol on colonic transit. Aliment Pharmacol Ther 2005 21 : 259 68.
10. Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002 47 : 2222 30.
11. Pampati V, Fogel R. Treatment options for primary constipation. Curr Treat Options Gastroenterol 2004 7 : 225 33.
12. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: Systematic review. Am J Gastroenterol 2005 100 : 936 71.
13. Brandt LJ, Prather CM, Quigley EMM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005 100 : S5 22.
14. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005 100 : S1 4.
15. Cash BD, Lacy BE. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol 2006 2 : 736 49.
16. Kamm MA, Muller-Lissner SA, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005 100 : 362 72.
17. Johanson JF, Wald A, Tougas G, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind controlled trial. Clin Gastroenterol Hepatol 2004 5 : 796 805.
18. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004 287 : C1178 83.
19. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003 111 : 931 43.
20. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: Mechanisms and implications for disease. Physiol Rev 2002 82 : 245 89.
21. Johnson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007 25 : 1351 61.
22. Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance, and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil 2005 17 : 78.
23. Camilleri M, Bharaucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006 290 : G946 7.
24. Amitiza [package insert]. Bethesda, MD : Sucampo Pharmaceuticals, Inc., 2006.
25. Mohammad-Panah R, Gyomorey K, Rommens J, et al. CIC-2 contributes to native chloride secretion by a human intestinal cell line, CACO-2. Biol Chem 2001 276 : 8306 13.
26. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004 2 : 895 904.
27. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 8.
28. Ueno R, Osama H, Habe T, et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels (abstract). Gastroenterology 2004 126 : A 100.